Azithromycin SR
DrugAzithromycin SR, 2.0 g by mouth (PO) x 1
NCT Number: NCT01032174
The purpose of this study is to compare compliance between patients with Acute Bacterial Sinusitis (ABS) treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of ABS in outpatient clinic practice.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i.purulent nasal discharge ii.purulent drainage in the posterior pharynx iii.purulent discharge from the maxillary sinus orifice
Two or more of the following:
Exclusion criteria
Azithromycin SR, 2.0 g by mouth (PO) x 1
Amoxiclav 1000 mg x twice daily, 10 days
Time frame: Day 11
Participant reported outcome questionnaire was the assessment of participant's convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered 'very convenient' or 'somewhat convenient' and 0 if participant answered 'not convenient' or 'not at all convenient'.
Time frame: Day 11
Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).
Time frame: Day 11
Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.
Pfizer
Industry
Acronym: EASY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00683371
Hypersensitivity, Immune System Diseases
San Francisco, California, United States
View Trial DetailsNCT00668304
Infections, Maxillary Sinusitis
Birmingham, Alabama, United States
View Trial DetailsNCT00537563
Infections, Maxillary Sinusitis
Bridgewater, New Jersey, United States
View Trial DetailsNCT00236652
Infections, Maxillary Sinusitis
View Trial Details